» Articles » PMID: 38095764

DNA Repair in Tumor Radioresistance: Insights from Fruit Flies Genetics

Overview
Publisher Springer
Date 2023 Dec 14
PMID 38095764
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiation therapy (RT) is a key anti-cancer treatment that involves using ionizing radiation to kill tumor cells. However, this therapy can lead to short- and long-term adverse effects due to radiation exposure of surrounding normal tissue. The type of DNA damage inflicted by radiation therapy determines its effectiveness. High levels of genotoxic damage can lead to cell cycle arrest, senescence, and cell death, but many tumors can cope with this damage by activating protective mechanisms. Intrinsic and acquired radioresistance are major causes of tumor recurrence, and understanding these mechanisms is crucial for cancer therapy. The mechanisms behind radioresistance involve processes like hypoxia response, cell proliferation, DNA repair, apoptosis inhibition, and autophagy.

Conclusion: Here we briefly review the role of genetic and epigenetic factors involved in the modulation of DNA repair and DNA damage response that promote radioresistance. In addition, leveraging our recent results on the effects of low dose rate (LDR) of ionizing radiation on Drosophila melanogaster we discuss how this model organism can be instrumental in the identification of conserved factors involved in the tumor resistance to RT.

Citing Articles

Molecule interacting with CasL-2 enhances tumor progression and alters radiosensitivity in cervical cancer.

Teng Y, Zhao H, Xue G, Zhang G, Huang Y, Guo W J Transl Med. 2025; 23(1):44.

PMID: 39799334 PMC: 11725214. DOI: 10.1186/s12967-024-06065-y.


Transcription Impairment of TMEM208 by ZBTB14 Suppresses Breast cancer Radiotherapy Resistance.

Li Y, Liang L J Mammary Gland Biol Neoplasia. 2024; 29(1):20.

PMID: 39692812 PMC: 11655580. DOI: 10.1007/s10911-024-09573-1.


A nomogram with Nottingham prognostic index for predicting locoregional recurrence in breast cancer patients.

Zheng J, Zeng B, Huang B, Wu M, Xiao L, Li J Front Oncol. 2024; 14:1398922.

PMID: 39351357 PMC: 11439878. DOI: 10.3389/fonc.2024.1398922.


HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.

Cassandri M, Porrazzo A, Pomella S, Noce B, Zwergel C, Aiello F Cell Death Discov. 2024; 10(1):351.

PMID: 39107280 PMC: 11303816. DOI: 10.1038/s41420-024-02115-y.

References
1.
Abad E, Graifer D, Lyakhovich A . DNA damage response and resistance of cancer stem cells. Cancer Lett. 2020; 474:106-117. DOI: 10.1016/j.canlet.2020.01.008. View

2.
Baumann M, Krause M, Hill R . Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008; 8(7):545-54. DOI: 10.1038/nrc2419. View

3.
Mohan R, Grosshans D . Proton therapy - Present and future. Adv Drug Deliv Rev. 2016; 109:26-44. PMC: 5303653. DOI: 10.1016/j.addr.2016.11.006. View

4.
Schaue D, McBride W . Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015; 12(9):527-40. PMC: 8396062. DOI: 10.1038/nrclinonc.2015.120. View

5.
Chandra R, Keane F, Voncken F, Thomas Jr C . Contemporary radiotherapy: present and future. Lancet. 2021; 398(10295):171-184. DOI: 10.1016/S0140-6736(21)00233-6. View